-

Circle Pharma to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for difficult-to-treat cancers, today announced that management will participate in two upcoming investor conferences:

Morgan Stanley 23rd Annual Healthcare Conference
1X1 Meetings: Monday, September 8, 2025
Location: New York, NY

Oppenheimer Life Sciences Private Company Showcase
1X1 Meetings: Thursday, September 25, 2025
Location: Virtual

About Circle Pharma

Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop next-generation targeted therapies for cancer and other serious illnesses. The company’s proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies, including for historically undruggable targets. Circle Pharma’s pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. The company’s lead program, CID-078, is a cyclin A/B RxL inhibitor in Phase 1 clinical development for patients with advanced solid tumors. Circle Pharma is based in South San Francisco, CA. For additional information, please visit us at circlepharma.com and follow us on LinkedIn and X.

Contacts

Media:
Josie Butler
1AB
josie@1abmedia.com

Investors:
Steve Klass
1AB
steve@1abmedia.com

Industry:

Circle Pharma, Inc.

Release Versions
English

Contacts

Media:
Josie Butler
1AB
josie@1abmedia.com

Investors:
Steve Klass
1AB
steve@1abmedia.com

More News From Circle Pharma, Inc.

Circle Pharma Announces Poster Presentation Highlighting the Potential of CID-078, a First-in-class Oral Cyclin A/B RxL Inhibitor, at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

SAN FRANCISCO--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced an upcoming poster presentation highlighting the potential of CID-078 as a novel therapeutic option in pediatric cancers at the American Association for Cancer Research (AACR) Special Conference on Pediatric Cancer, taking place from September 25-28 in Boston, MA. CID-078 is a first-in-class, orally bioavailable m...

Circle Pharma Announces Agreement with Lilly to Further Enhance AI/ML Capabilities and Accelerate Development of New Oral Macrocycle Therapies

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for difficult-to-treat cancers, today announced an agreement with Eli Lilly and Company (Lilly) that enables the company to use Lilly TuneLab, a pioneering artificial intelligence and machine learning (AI/ML) platform designed to accelerate the development of new medicines by providing biotech companies access to powerful drug...

Circle Pharma Announces Publication in Nature Demonstrating Robust Pre-clinical Anti-tumor Activity of Cyclin A/B RxL Inhibition

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for difficult-to-treat cancers, today announced a Nature publication describing robust pre-clinical tumor suppression and novel mechanistic insights from inhibiting the binding of certain protein substrates (that bind via RxL motifs) to cyclins A and B in E2F-high tumor cells. Circle Pharma’s oral cyclin A/B RxL inhibitor, CID-...
Back to Newsroom